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Abstract 
Objective:  To describe the prevalence of vitamin D deficiency among antiretroviral 
treatment (ART)-naïve, HIV positive individuals. 
Methods: We reviewed records of consecutive ART-naïve patients, registering for care 
for the first time at a London clinic from 01/01/2008 to 31/12/2009. During this period, 
serum 25-hydroxycholecalciferol (25-OHD) was measured routinely for all new patients. 
25-OHD deficiency and severe deficiency were defined as ≤50 and ≤25 nmol/L, 
respectively.   
Results: Among 253 patients (82% male, median age 36 years, 64% white ethnicity), 148 
(58.5%) were 25-OHD deficient, including 32 (12.6%) who were severely deficient. 
73.5% (61/83) patients of non-white ethnicity were 25-OHD deficient compared with 
50.7% (76/150) of those reporting white ethnicity (p<0.001).  Seven of eight (87.5%) 
patients with hypocalcaemia (<2.12nmol/L) were 25-OHD deficient. The prevalence of 
25-OHD deficiency was higher in winter and spring vs. summer and autumn (89/129 
[69.0%] vs. 59/124 [47.6%], p<0.001). Serum 25-OHD deficiency was not associated 
with gender, CD4 count, HIV viral load or clinical stage.  
Conclusion: Serum 25-OHD deficiency was common among ART-naïve patients, with 
those of non-white ethnicity at highest risk. CD4 count, HIV viral load and HIV clinical 
staging do not help to identify those at risk, but low serum calcium should prompt 
investigation of 25-OHD levels. 
 
 
KG 2013: Vitamin D deficiency in ART-naïve patients 3 
Introduction 
In addition to vitamin D‟s established role in bone metabolism, vitamin D deficiency is 
reported to be associated with a variety of medical conditions including diabetes, 
cardiovascular disease [1–5] and infectious diseases particularly tuberculosis and HIV 
[6–11]. 
Studies investigating vitamin D‟s role in HIV infection have been conflicting but 
associations with an increased risk of HIV acquisition and progression to advanced HIV 
have been shown [9,12,13] . Vitamin D deficiency is also speculated to be associated 
with an increased risk of cardiovascular disease in non-HIV infected populations [2–5].  
One study demonstrated an association between lower vitamin D levels and greater 
common carotid artery intimal thickness values in HIV positive individuals [14].  Severe 
vitamin D deficiency (serum 25-hydroxycholecalciferol (25-OHD) concentration 
<10μg/ml or <25nmol/L) has also been associated with increased levels of serum 
inflammatory markers including IL-6 and hsCRP [15] indicating vitamin D deficiency as 
a risk factor for cardiovascular disease specifically in the HIV population. 
 
Specifically, HIV positive individuals are speculated to be at increased risk of vitamin D 
deficiency [10,11,13,16–18].  Dark-skinned individuals in the UK have a higher risk of 
vitamin D deficiency; one study of over eight hundred patients from Birmingham 
revealed a prevalence of vitamin D deficiency (25-OHD <10 μg/L) of 26% among Afro-
Caribbeans and 31% among Asians compared to 12% of Caucasians [19] . As many HIV 
positive individuals in the UK are migrants from African countries, this may in part 
explain the high prevalence observed.   
KG 2013: Vitamin D deficiency in ART-naïve patients 4 
Recent studies in the UK investigating the prevalence of vitamin D deficiency in HIV 
positive individuals have involved populations where the majority of individuals were of 
black ethnicity [16,17].  Importantly, previous studies have also investigated the 
prevalence of vitamin D deficiency predominantly in individuals established on 
antiretroviral treatment (ART) [10,16–18].  ART itself is associated with vitamin D 
deficiency, non-nucleoside reverse transcriptase inhibitors (NNRTI‟s) and protease 
inhibitors (PI‟s) appear to interfere with vitamin D metabolism [17,18,20–22] whereas 
tenofovir may be a culprit by decreasing bone mineralisation and causing secondary 
hyperparathyroidism through effects on renal phosphate regulation [16,23].  The impact 
of immune reconstitution on vitamin D levels is less clear. 
A recent systematic review of the literature on vitamin D deficiency in HIV infection 
reported that vitamin D deficiency, secondary hyperparathyroidism and low bone mineral 
density were common in HIV positive patients but that HIV infection may not be 
specifically associated with vitamin D deficiency (24).  Importantly all the studies 
reviewed investigating vitamin D deficiency were observational studies that included 
HIV positive patients on ART or who were ART experienced. Although some adjusted 
for ART use and individual ART/drug classes, they are still subject to confounding. 
The objective of this study was to describe the prevalence of vitamin D deficiency 
specifically among ART-naïve individuals newly diagnosed with HIV in a central 
London clinic. 
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Methods 
Patients registering for HIV care between 01/01/2008 and 31/12/2009 for the first time at 
the Mortimer Market centre, a large HIV clinic in central London were included in this 
retrospective record review. During this period, serum 25-OHD levels were measured 
routinely for new patients registering for HIV care. We restricted the analysis to ART-
naïve patients with an available serum 25-OHD result, all patients included were not 
taking vitamin D supplements. Vitamin D status was defined as “normal” when 25-OHD 
was >50nmol/L, “deficient” when 25-OHD ≤50nmol/L and “severely deficient" when 
25-OHD was ≤25nmol/L. 
 
We reviewed data fields including demographics, CD4 cell count, HIV RNA viral load; 
self-reported ethnicity; season when the 25-OHD sample was taken (winter [December – 
February]; spring [March – May]; summer [June – August]; autumn [September - 
November]); serum glucose, calcium, phosphate, alkaline phosphatase (ALP) and HIV 
clinical stage (asymptomatic; symptomatic; AIDS, as recorded by the clinician).  
Continuous data were grouped into categories and Fisher‟s exact test was used to assess 
associations.  Associations with vitamin D deficiency were explored by calculating 
unadjusted odds ratios. 
 
This was a retrospective audit of anonymised data and specific ethical approval was not 
requested. 
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Results 
Among 253 patients fulfilling inclusion criteria, 207 (81.8%) were male and the median 
age was 36 years (range 16 - 75 years).  Among 233 with ethnicity data available, 150 
(64.4%) were white, and 83 (35.6%) black or other ethnicity. The median CD4 count and 
HIV viral load were 450 cells/mm
3
 (range 10 – 1100 cells/mm3) and 8,600 copies/mL 
(range; less than 50copies/ml  – 11,000,000 copies/mL) respectively.  236 (93.3%) 
presented with asymptomatic HIV infection. 
 
Among 253, 148 (58.5%) patients were 25-OHD deficient (25-OHD ≤50nmol/L), 
including 32 (12.6%) who were severely deficient (25-OHD ≤25 nmol/L) (Table 1). 
Among 83 patients of non-white ethnicity 61, (73.5%) were 25-OHD deficient compared 
with 50.7% (76/150) of those reporting white ethnicity (p<0.001).  
Seven of eight (87.5%) patients with hypocalcaemia (<2.12 mmol/L) were 25-OHD 
deficient, as were seven of 15 (46.7%) with hypophosphataemia (<0.8mmol/L) and seven 
of 11 (63.6%) with high alkaline phosphatase (>130IU/L).  There was no association 
between 25-OHD deficiency and hypophosphataemia. The prevalence of 25-OHD 
deficiency was higher in winter and spring vs. summer and autumn (89/129 [69.0%] vs. 
59/124 [47.6%], p<0.001). Serum 25-OHD deficiency was not associated with age, 
gender, CD4 count, HIV viral load, serum glucose or HIV clinical stage. 
On univariable analysis, there was trend towards vitamin D deficiency and 
hypocalcaemia [p=0.14, odds ratio 5.44 (95% confidence interval 0.7 – 45.0)] larger 
numbers may have produced a significant association and a smaller confidence interval 
with these results reflecting small numbers. Season and ethnicity were the only factors 
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significantly associated with vitamin D deficiency on univariable analysis (where 
p<0.05), therefore unadjusted odds ratios were calculated to report measures of 
association for season and ethnicity (see table). 
 
Discussion 
This study found a high prevalence of vitamin D deficiency among newly diagnosed, 
ART-naïve patients; which, therefore cannot be attributed to the effect of antiretroviral 
agents.  Our study used a vitamin D level of ≤50nmol/L to define deficiency, optimal 
vitamin D status is reflected by serum concentrations of 25-OHD of 75 nmol/l (30 μg/l) 
and above [5].  We found that 58.5% were deficient including 75% reporting black 
ethnicity and 51% of those reporting white ethnicity.  This compares with a study in 
South London which found that 57% (131 of 227 HIV positive subjects) were vitamin D 
deficient (<50nmol/L), however in their study population only 15% (33/227) were ART-
naïve and over two thirds of the sample were of black ethnicity [16].  Another study in 
South London of 1077 HIV positive patients found that 73.5% were vitamin D deficient 
(<50nmol/L) but only 12.4% of their study population were ART-naïve and 60% were of 
black ethnicity [17]. 
 
A recent study investigating vitamin D levels in Swiss HIV-positive patients found a 
positive association between vitamin D and time since HIV diagnosis on multivariable 
analysis.  They speculated that this may be related to the potential poorer health of 
recently diagnosed patients, however the relationship to ART use was unclear [18]. 
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As expected, we found a higher prevalence of vitamin D deficiency in non-white ethnic 
groups and an association in the winter and spring months [1,8,16–19]. There were no 
other demographic factors, which identified individuals at higher risk. Among 
biochemical variables, most of our patients with hypocalcaemia were vitamin D 
deficient; but a significant association was not observed probably due to relatively small 
numbers.  Other markers of bone metabolism (phosphate, alkaline phosphatase) were not 
associated with vitamin D deficiency. 
 
Our study population was predominantly white males with asymptomatic HIV infection, 
however it has demonstrated a high prevalence of vitamin D deficiency in HIV positive, 
ART-naïve individuals, which thus cannot be attributed to ART.  The only clinical factor 
associated with vitamin D deficiency was non-white ethnicity.  This suggests that all HIV 
positive individuals should be considered for routine screening, particularly individuals 
of non-white ethnicity.  CD4 count, HIV viral load and HIV clinical staging do not help 
to identify those at risk, but low serum calcium should prompt investigation of 25-OHD 
levels. 
KG 2013: Vitamin D deficiency in ART-naïve patients 9 
References 
 
1.  Tahrani AA, Ball A, Shepherd L, Rahim A, Jones AF, Bates A. The prevalence of 
vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK. 
Int J Clin Pract. 2010 Feb;64(3):351–5.  
2.  Cheng S, Massaro JM, Fox CS, Larson MG, Keyes MJ, McCabe EL, et al. 
Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. 
Diabetes. 2010 Jan;59(1):242–8.  
3.  Judd SE, Tangpricha V. Vitamin D deficiency and risk for cardiovascular disease. 
Am J Med Sci. 2009 Jul;338(1):40–4.  
4.  Kilkkinen A, Knekt P, Aro A, Rissanen H, Marniemi J, Heliövaara M, et al. 
Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol. 
2009 Oct 15;170(8):1032–9.  
5.  Pearce SHS, Cheetham TD. Diagnosis and management of vitamin D deficiency. 
BMJ. 2010;340:b5664.  
6.  Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V. Vitamin D 
for Treatment and Prevention of Infectious Diseases: A Systematic Review of 
Randomized Controlled Trials. Endocrine Practice. 2009 Jul 1;15(5):438–49.  
7.  Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ. Vitamin D in the 
treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol. 2007 Mar;103(3-
5):793–8.  
8.  Ustianowski A, Shaffer R, Collin S, Wilkinson RJ, Davidson RN. Prevalence and 
associations of vitamin D deficiency in foreign-born persons with tuberculosis in 
London. J Infect. 2005 Jun;50(5):432–7.  
9.  Villamor E. A potential role for vitamin D on HIV infection? Nutr Rev. 2006 
May;64(5 Pt 1):226–33.  
10.  Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in 
vitamin D deficiency following antiretroviral regime change: Results from the 
MONET trial. AIDS Res Hum Retroviruses. 2011 Jan;27(1):29–34.  
11.  Yin M. Vitamin D, bone, and HIV infection. Top Antivir Med. 2012 
Dec;20(5):168–72.  
12.  Mehta S, Hunter DJ, Mugusi FM, Spiegelman D, Manji KP, Giovannucci EL, et al. 
Perinatal outcomes, including mother-to-child transmission of HIV, and child 
mortality and their association with maternal vitamin D status in Tanzania. J Infect 
Dis. 2009 Oct 1;200(7):1022–30.  
KG 2013: Vitamin D deficiency in ART-naïve patients 10 
13.  Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, et al. 
Vitamin D status of HIV-infected women and its association with HIV disease 
progression, anemia, and mortality. PLoS ONE. 2010;5(1):e8770.  
14.  Ross AC, Judd S, Kumari M, Hileman C, Storer N, Labbato D, et al. Vitamin D is 
linked to carotid intima-media thickness and immune reconstitution in HIV-positive 
individuals. Antivir Ther (Lond). 2011;16(4):555–63.  
15.  Ansemant T, Mahy S, Piroth C, Ornetti P, Ewing S, Guilland J-C, et al. Severe 
hypovitaminosis D correlates with increased inflammatory markers in HIV infected 
patients. BMC Infect Dis. 2013;13:7.  
16.  Rosenvinge MM, Gedela K, Copas AJ, Wilkinson A, Sheehy CA, Bano G, et al. 
Tenofovir-linked hyperparathyroidism is independently associated with the 
presence of vitamin D deficiency. J Acquir Immune Defic Syndr. 2010 
Aug;54(5):496–9.  
17.  Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, et al. Efavirenz is 
associated with severe vitamin D deficiency and increased alkaline phosphatase. 
AIDS. 2010 Jul 31;24(12):1923–8.  
18.  Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, et al. High 
prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive 
and successfully treated Swiss HIV patients. AIDS. 2010 May 15;24(8):1127–34.  
19.  Ford L, Graham V, Wall A, Berg J. Vitamin D concentrations in an UK inner-city 
multicultural outpatient population. Ann Clin Biochem. 2006 Nov;43(Pt 6):468–73.  
20.  Brown TT, McComsey GA. Association between initiation of antiretroviral therapy 
with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther (Lond). 
2010;15(3):425–9.  
21.  Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-
protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. 
AIDS. 2003 Mar 7;17(4):513–20.  
22.  Bouvier G. Protease inhibitors can interfere with vitamin D metabolism. HIV Clin. 
2009;21(3):9–10.  
23.  Klassen K, Martineau AR, Wilkinson RJ, Cooke G, Courtney AP, Hickson M. The 
Effect of Tenofovir on Vitamin D Metabolism in HIV-Infected Adults Is Dependent 
on Sex and Ethnicity. Slominski AT, editor. PLoS ONE. 2012 Sep 12;7(9):e44845.  
24.  Childs K, Welz T, Samarawickrama A, Post FA. Effects of vitamin D deficiency 
and combination antiretroviral therapy on bone in HIV-positive patients. AIDS. 
2012 Jan 28;26(3):253–62.  
 
KG 2013: Vitamin D deficiency in ART-naïve patients 11 
 
 Table: Prevalence of vitamin D deficiency by demographic characteristics and 
relevant laboratory variables 
 
 
Total Sample 
(n=253)  
Normal 
Vitamin D 
(>50nmol/L) 
Deficient 
Vitamin D 
(≤50nmol/L)  
p-value 
(Fishers 
Exact) 
Odds ratio  
(95% confidence 
interval) 
Sex, n (%) 
Male 
Female 
 
207 (81.8%) 
46 (18.2%) 
 
90 (43.5%) 
15 (32.6%) 
 
117 (56.5%) 
31 (67.4%) 
 
p=0.19 
 
Age Range 
<30 
31 – 40 
>40 
 
80 (31.6%) 
88 (34.8%) 
85 (33.6%) 
 
48 (60%) 
52 (59.1%) 
48 (56.5%) 
 
32 (40%) 
36 (40.9%) 
37 (43.5%) 
 
p=0.90 
 
Ethnicity, n (%) 
(excl unknown, n=233) 
 
White 
Black 
Other/non-white (Asian, 
Chinese, mixed race) 
 
 
 
150 (59.3%) 
63 (24.9%) 
20 (8.6%) 
 
 
 
74 (49.3%) 
16 (25.4%) 
6 (30%) 
 
 
 
76 (50.7%) 
47 (74.6%) 
14 (70%) 
 
 
 
p=0.01 
 
Ethnicity, n (%) 
(excl unknown, n=233) 
White 
Non white 
 
 
150 (64.4%) 
83 (35.6%) 
 
 
74 (49.3%) 
22 (55.4%) 
 
 
76 (50.7%) 
61 (73.5%) 
 
 
p<0.001 
 
 
2.7 (1.5 – 4.8) 
Season, n (%) 
Summer/Autumn 
Winter/Spring 
 
124 (49%) 
129 (51%) 
 
65 (52.4%) 
40 (31%) 
 
59 (47.6%) 
89 (69%) 
 
p=0.001 
 
2.5 (1.5 – 4.1) 
KC60* HIV Stage, n (%) 
 E1 (asymptomatic) 
 E2 (symptomatic) 
 E3 (AIDS) 
 
236 (93.3%) 
7 (2.8%) 
10 (3.95%) 
 
135 (57.2%) 
6 (85.7%%) 
7 (70%) 
 
 
101 (42.8%) 
1 (14.3%) 
3 (30%) 
 
 
p=0.241 
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* the KC60 code, is a Health Protection Agency (HPA) required „diagnoses made‟ and „services provided‟ 
code provided by all genitourinary clinic services in the UK for each patient presentation; for the purpose 
of internal management, audit and reporting data to the HPA. 
 
 
 
 
 
CD4 count (cells/mm3 x10) 
(missing values) 
Median  
IQR 
 
(12/253) 
0.45 
0.60 – 0.30 
 
(9/148) 
0.43 
0.59 – 0.25 
 
(3/105) 
0.47 
0.61 – 0.36 
 
p=0.651 
 
HIV viral load (copies/mL) 
(missing values) 
Median  
IQR 
 
(9/253) 
8,600 
66,500 – 335 
 
(6/148) 
8,450 
70,000 – 110 
 
(3/105) 
11,500 
62,000 – 730 
 
p=0.374 
 
 
 
Calcium (mmol/L) 
Normal (2.12 -2.65) 
Hypocalcaemia (<2.12) 
 
224(96.5%)  
8 (3.5%) 
 
 
98 (43.7%) 
1 (12.5%) 
 
 
126 (56.3%) 
7 (87.5%) 
 
 
p=0.14 
 
5.4 (0.7 – 45.0) 
Phosphate (mmol/L) 
Normal (0.8-1.4) 
Hypophosphataemia 
(<0.8) 
 
210 (90.5%) 
15 (6.5%) 
 
89 (42.4%) 
8 (53.3%) 
 
 
121 (57.6%) 
7 (46.7%) 
 
p=0.43 
 
ALP (IU/L) 
Normal (30-130) 
High ALP (>130) 
 
233 (95.1%) 
11 (4.5%) 
 
98 (42.1%) 
4 (36.4%) 
 
135 (57.9%) 
7 (63.6%) 
 
p=0.77 
 
